Enhanced responses to vasoconstriction induced by neuropeptide Y and α 2 -adrenoceptor agonists have been seen following pharmacological activation of the adenylyl cyclase (AC) system. Since preliminary studies revealed only minor responses to angiotensin II (Ang II) in human omental arteries, we have investigated whether enhanced activity of AC may unravel further functional Ang II receptors. Human omental arteries were obtained in conjunction with elective gut surgery. After dissection of the vessel, the endothelium was removed by 10 sec of Triton X-100 treatment. Ring segments (1-2 mm long) were mounted on a myograph and studied. Ang II produced small contractions, 27±5% relative to the response elicited by 60 mM K + . However, enhanced Ang II (105±10%, p<0.001) responses were seen during AC activation by forskolin (0.1-1 µM). This enhanced contractile response to Ang II was not inhibited by the angiotensin II type 2 (AT 2 -receptor antagonist PD 123319 (0.1 µM), but was blocked in an insurmountable way by the angiotensin II type 1 (AT 1 )-receptor antagonist candesartan (1 nM) and in a surmountable manner by losartan (0.1 µM) and irbesartan (0.1 µM). Pertussis toxin (a Gi-protein blocker) and the protein kinase C inhibitor, RO31-8220 (0.01, 0.1 and 1 µM), markedly reduced this response, while the protein kinase A inhibitor, H89 (1, 10 µM), had no effect. RT-PCR provided evidence for the presence of mRNA for both AT 1 -and AT 2 -receptors. The results suggest that both a cAMP-dependent and a cAMP-independent mechanism are involved in the contractile responses to Ang II in human omental arteries and that both responses are mediated via the AT 1 -receptor.
Introduction
In several cardiovascular disorders, blockade of the renin-angiotensin-aldosterone system (RAAS) by angiotensin-converting enzyme inhibitors (ACE-I) has been found to prevent or delay disease progression. 1 Owing to side-effects of ACE-I, and to provide more specific and efficacious treatment, angiotensin II type 1 (AT 1 )-receptor blockers were developed. 2 At present, only two angiotensin receptors have been identified in man, the AT 1and AT 2 -receptors, which are members of the G protein-coupled, seven transmembrane-domain receptor superfamily. Experimental studies have revealed that angiotensin II (Ang II) produces vasoconstriction via AT 1 -receptors, while the AT 2receptor can induce cell differentiation, tissue repair and antiproliferation. 1, 3 All the well-known vasomotor effects of Ang II are mediated by AT 1receptors. 4, 5 Thus, blockade of AT 1 -receptors may leave the AT 2 -receptor untouched and able to mediate potentially beneficial effects on the vasculature.
Ang II is generally considered to induce vasoconstriction through a direct mechanism. 4, 6 However, in preliminary studies it produced only a weak, if any, constrictor response in human omental arteries. The possibility that the capacity of the AT 1 -receptor is underestimated under these assay conditions was therefore examined. Recent pharmacological studies have demonstrated that enhanced contractile responses to neuropeptide Y 7 or to α 2 -adrenoceptor agonists 8 can be obtained following prior pharmacological manipulation of the adenylyl cyclase (AC) system. 9 The present study was designed to investigate the putative involvement of AC in response to Ang II in human omental arteries, to characterise the angiotensin receptor subtype involved and possible messenger pathways activated. In addition, the expression of mRNA for AT 1 -and AT 2 -receptors was studied by reverse transcription-polymerase chain reaction (RT-PCR).
Methods

Tissue collection
Omental arteries were removed from patients (n=15, 14 males and one female, aged 34-85 years) undergoing elective gut surgery. The Human Ethics Committee of the Lund University approved the study. All subjects were informed and agreed to participate in the study.
The vessels were placed in buffer solution aerated with 95% O 2 /5% CO 2 and transported to the laboratory, where they were cleaned of excess connective tissue, cut into ring segments and then used in tissue bath studies.After dissection of the vessels, the endothelium was removed by 10 sec of Triton X-100 treatment, 10 in order to avoid the confounding influence of the endothelium. The success of the procedure was verified by the lack of relaxation to acetylcholine in precontracted vessels. 10 Segments of isolated omental arteries were mounted on two L-shaped metal prongs, one of which was connected to a force-displacement transducer (FT03C, Grass, USA), attached to a Macintosh computer for continuous recording of the isometric tension, and the other to a displace-ment device. 11 The position of the holder could be changed by means of a movable unit, allowing fine adjustments of the vascular tension by varying the distance between the metal prongs. The experiments were continuously recorded by the software program Chart V 3.5 (MacLab, AD Instruments UK). The specimens were immersed in temperature-controlled (37°C) tissue baths, containing a buffer solution of the following composition (mM): NaCl 119; NaHCO 3 15; KCL 4.6; MgCl 2 1.2; NaH 2 PO 4 1.2; CaCl 2 ,1.5; glucose 5.5. The solution was continuously aerated with 95% O 2 /5% CO 2 , resulting in a pH of 7.4. Depending on the vessel size (0.5-0.8 mm outer diameter, 1-2 mm long), a tension of 1.5-2.5 mN was applied. Owing to initial spontaneous relaxation of the vessel segments, it was necessary to make several adjustments of tone with the movable holder, in order to maintain a stable resting tension. After approximately 1 hour, when the tension had stabilised at the desired level, each vessel segment was exposed to a buffer solution, containing 60 mM KCl, obtained by substituting equimolar concentrations of NaCl for KCl in the buffer solution described above. Only those segments which responded with a potassium-induced contraction (>1 mN), that was reproducible a second time after washout with standard buffer solution, were used in subsequent experiments.
Experiment protocol
After another rest for 1 hour, some of the segments were used as controls, while other segments were pretreated with antagonists for 60 minutes. All those segments were exposed to the thromboxane-mimetic U46619 (0.1 mM) and relaxed back to baseline with the AC-activator forskolin (0.1-1 µM), before the cumulative application of Ang II. Some tests were also performed with Ang II alone, without precontraction and forskolin treatment. All experiments were run in parallel. Each vessel segment was only exposed to Ang II on one occasion. After this, the segment was discarded, in order to avoid any possible tachyphylatic interference. Some tests were done to compose the concentration-response curve using cumulative and fractionate exposures; however, there was no difference (data not shown).
Drugs
Candesartan, irbesartan and losartan (generous gifts from Dr P Morsing,Astra Zeneca, Sweden), H89 and RO31-8220 (Gibco, BRL), PD 123319, U46619, forskolin, acetylcholine, Ang II and pertussis toxin (Sigma, USA) were dissolved and diluted in saline. Stock solutions were kept at -40°C until use.
Calculation and statistics
Data are expressed as mean values± standard error of the mean; n refers to the number of patients from which the vessel segments were obtained. Contractile responses in each segment were expressed as the percentage of the contraction induced in that segment by 60 mM K + , and the maximum contractile effects of an agonist were indicated as E max values. The pD 2 , the negative logarithm of the molar concentration that produced half-maximum contraction, was calculated from the straight-line equation between the concentration above and below the midpoint of the concentration-response curve. The material was tested by one-way ANOVA for differences between groups. Differences were considered significant at p values <0.05. The dissociation constant, pK B , was calculated as described by Tallarida et al. 12 
RNA preparation
Total RNA from human omental arteries was isolated, using the TRIzol reagent (Life Technologies, Gaithersburg, USA) following the supplier's protocol. The cells were kept in a medium containing 10% HS and 10% FCS until confluence and then homogenised in TRIzol. The RNA was precipitated with isopropanol, washed with 75% ice-cold ethanol, air-dried and finally redissolved in 20 µL diethyl-pyrocarbonate (DEPC)-treated water. The RNA concentration was determined spectrophotometrically. Estimating the ratio of 18S/28S RNA on a denaturing gel assessed the quality of the RNA preparation. 
Reverse transcription-polymerase chain reaction (RT-PCR)
The reverse transcription of total RNA to cDNA and subsequent PCR were carried out with the GeneAmp RNA PCR kit (Perkin Elmer, Foster City, USA) in a Perkin Elmer DNA Thermal Cycler. First Strand cDNA was synthesised from 1 µg total RNA in a 20 µL reaction volume, using random hexamers as primers.The reaction mixture was incubated at 42°C for 15 minutes, heated to 99°C for 5 minutes, then chilled to 5°C for 5 minutes. A 5 µL portion of the resultant cDNA was amplified by PCR in a final volume of 50 µL, following a standard PCR protocol. AmpliTaq DNA polymerase (Perkin Elmer) was used as the thermostable enzyme. The PCR was carried out with the following profile: 2 minutes at 95°C for one cycle; 1 minute at 72°C for one cycle; incubation at 4°C for 5 minutes and PCR without the RT-step (data not shown) were included in all experiments.
The following primers, which were designed, based on the published gene sequences, 13, 14 were used for amplification of human AT 1 -and AT 2 -receptors: AT 1 :Forward5'-GATGATTGTCCCAAAGCTG, Reverse 5'-TAGGRAARRGCCAAAGGCC, generating a 255 bp product. AT 2 : Forward 5'-AAGAAGAAATC-CCTGGCAAGC, Reverse 5'-CTTGGTCACGGGT-TATCCTGT, generating a 302 bp product.
Results
Effect of Ang II in forskolin-treated vessels
Ang II (1 pM-0.3 µM) caused only a minor contraction of human omental arteries at resting tone, which was 27±5% (n=12) of the maximal response to 60 mM K + . However, a significantly enhanced Ang II response was obtained when the vessel segment was first precontracted with 0.1 µM U46619, and relaxed back to baseline with 0.1-1 µM forskolin, prior to the cumulative addition of Ang II (105±10%, n=15) (p<0.001) ( Figure 1 ).
Effect of candesartan and PD 123319 on Ang II-induced contraction
Pretreatment of the arteries with candesartan, (1 nM) for 1 hour, almost fully suppressed the Ang IIinduced contractions to 13±5% (n=8, p<0.001 vs. control), but there was no effect with the AT 2 -recep-tor blocker PD 123319, 0.1 µM (98±7%, n=11) ( Figure 2 ). In addition, the weak Ang II responses in untreated vessels were antagonised by candesartan (1 nM) (5±1%) (p<0.001).
Effect of losartan and irbesartan on Ang II responses
Losartan (0.1 µM) and irbesartan (0.1 µM), two competitive AT 1 -receptor antagonists, caused parallel rightward shifts of the concentration-response curves to Ang II (E max =93±7%, pD 2 =7.28±0.37, n=5 and E max =99±10%, pD 2 =7.07±0.18, n=5; respectively). The maximum contraction to Ang II was not significantly changed by either antagonist, compared with control (E max =105±10%, pD 2 =8.92±0.18) ( Figure 2 ).The dissociation constant pK B for losartan was calculated as 9.46±0.01 and for irbesartan as 8.45±0.01 (Figure 3 ).
Effect of pertussis toxin
In segments preincubated with pertussis toxin (100 ng/ml) for 1 hour, the Ang II-induced contractions were significantly reduced.These contractions were 22±7% (n=4;p<0.005) vs. control (105±10%) (n=15) without any difference in pD 2 (8.92±0.18 vs. 9.27±0.05; p>0.05) ( Figure 4 ).
Effect of the specific PKC inhibitor, RO31-8220
The effect of RO31-8220 (1, 0.1, 0.01 µM) on Ang IIinduced contractile responses in human omental arteries is shown in Figure 5A . Increasing concentrations of RO31-8220 resulted in a progressive decrease in the maximum contractile response to Ang II, which was significant at both 10 -7 and 10 -6 M (p<0.05).
Effect of the specific PKA inhibitor, H89
Ang II responses were not significantly different from control following treatment with H89 (1 and 10 µM) ( Figure 5B ).
AT 1 -and AT 2 -receptor expression
Agarose gel electrophoresis of the RT-PCR products from human omental arteries demonstrated products of the expected size, corresponding to mRNA encoding the human AT 1 -receptors (255 bp) and AT 2 -receptors (302 bp). No bands were detected in negative controls where the reverse transcriptase enzyme was omitted in the first strand cDNA reaction.Thus, we can conclude that mRNA for both angiotensin AT 1 -and AT 2 -receptors are present in human omental arteries ( Figure 6 ).
Discussion
The vasoconstrictor response to Ang II is very variable in human vessels, largely dependent on the source of the blood vessels.The responses in subcutaneous arteries or omental arteries is unaffected by AT 2 -receptor blockade 15 while a slightly increased contraction can be seen in pregnant rat uterine artery. 16 The selective AT 2 -receptor antagonist, PD 123319, did not, in the present study, modify the contraction to Ang II in forskolintreated omental arteries, suggesting that the AT 2receptor was not present to a functionally significant degree. This is in contrast to the RT-PCR results, which demonstrated the presence of mRNA for both AT 1 -and AT 2 -receptors. Any interference by the endothelium and a putative AT 2receptor in the present study was avoided by removal of the endothelium. As revealed by others, 15, 17 mechanical removal of the endothelium, or preincubation with a nitric oxide synthase inhibitor, the prostaglandin blocker indomethacin or an endothelin receptor antagonist, does not modify the Ang II contractile response. Thus, it is suggested that the contractile response of isolated human arteries to Ang II involves predominantly AT 1 -receptor activation, with no significant influence of endothelial factors. This agrees well with the observations in the present study, in which Ang II-induced contraction was blocked by candesartan in the de-endothelialised arteries.The RT-PCR results would imply that only the mRNA for the AT 1 -receptor is translated into functional receptors in vessel walls.
Recently, a mechanism was described for α 2adrenoceptors and neuropeptide Y Y 1 receptors, that may also be implicated also for angiotensin receptors. 8, 18 This involves cross-talk between receptor and effector systems and could represent an obligatory requirement for these receptors to produce contraction via a reduction in the levels of cAMP. This response was not affected by manipulation of the endothelium. For the contractile α 2adrenoceptor and the enhancement by neuropeptide Y, evidence for a cyclic AMP-dependent mechanism was provided by a set of studies in which forskolin was used to directly activate AC.This was verified by direct measurement of a correlation between relaxation to forskolin and tissue elevation of cAMP. 7, 8, 18 In the present study, we used this protocol after adjustment for human tissue sensitivity.The experiments were performed after first inducing a stable contraction with U46619 and subsequently a relaxation to baseline by activating AC with forskolin. 19 Thereafter, cumulative application of Ang II resulted in a strong concentrationdependent contraction, which reached the same level of contraction as the initial U46619 activation.This effect can be explained by the ability of Ang II to reduce cyclic AMP levels, thereby permitting the contractile response to U46619 to return to baseline (Figure 1) . The Ang II-induced response under these conditions was charac- 20, 21 The results appear to conform well with published data and strongly support activation of AT 1 -receptors. Losartan and irbesartan shifted the concentrationresponse curve of Ang II to the right, in a competitive manner and with dissociation constants that are in agreement with those published. 21 For candesartan, the pEC 50 was not altered but the E max markedly reduced, agreeing well with the insurmountable type of antagonism previously shown for this agent. 20 Thus, since the AT 2 -antagonist PD 123319 was without effect, we conclude that the contraction was mediated via the AT 1 -receptor subtype. Also, the weak direct contraction at resting tone was antagonised by candesartan, thus supporting the presence of an AT 1 -receptor also mediating this type of response. Since the contraction was weak and not in the scope of this study, no further experiments were carried out. However, we have shown in subcutaneous arteries that this is mediated by the AT 1 -receptor, acting via another G protein and involving elevation of intracellular Ca 2+ . 22 In order to characterise the receptor-coupling mechanisms in some detail, we used the Giprotein inhibitor, pertussis toxin. Pertussis toxin caused a significant depression of the Ang II concentration-response curve (Figure 4 ). The marked inhibition of the Ang II response suggests that the Gi-protein may be coupled to further intracellular mechanisms. 23 In the cascade leading to regulation of intracellular calcium ion homeostasis, protein kinases play a pivotal role. 24 In vascular smooth muscle, the contraction operates via the two major protein kinase A and C systems. 25, 26 In our study, we used RO31-8220 as a selective protein kinase C inhibitor 27 and H89, as a selective protein kinase inhibitor. 28 RO31-8220, but not H89, caused significant inhibition of the Ang II response. Our results therefore suggest that, under the present conditions, AT 1 -receptor activation in the omental artery is linked to an intracellular mechanism via a protein kinase C (PKC)-dependent pathway.
In conclusion, the present data suggest that the response to Ang II in human omental arteries is mediated by AT 1 -receptors. At resting tone, the Ang II response is weak, but in conjunction with elevated tone and activation of AC, a strong AT 1 -mediated contractile response is uncovered, which acts via a Gi-protein and PKC. 
